The potential association between PIK3CA mutational status and T-DM1 efficacy remains unknown, but the results from clinical breast cancer series suggest that trastuzumab benefit does not depend on the mutational status of PIK3CA[55,56] or tumor PTEN expression [57]. Here, PIK3CA is linked to breast carcinoma.